Taking advantage of highly sensitive MS-based metabolic profiling, we identified 2 robust circulating biomarkers, succinic-cysteine (suc-cys) and succinyl-adenosine (suc-ado), which can sensitively and specifically reflect FH status and tumor burden in RCC. This evidence concerns the gene FH and neoplasm.